GOOD buying opportunity, While the USA is in later-stage clinical trials, EMD is gaining experience and RWD on actually delivering the clinical service and wrap-around support. I can see the USA doing a deal here once they have approval, as arguably we will have the most experience of any company globally (no one in the USA will have the skills as its only able to be done at the research level), and leverage that into our mdma analogs.
Australia is deff a number of years ahead of any counterpart. and just like cannabis we will quickly grow our dataset from 0 to >10,000.
